The Real Cost of Peptide Therapy: What You'll Actually Pay in 2026

Let's talk about the elephant in the room when it comes to peptide therapy: the cost. You've probably heard the success stories and maybe even talked to your doctor about GLP-1 medications. Then you saw the price tag and felt your heart sink.

Here's the good news. The cost picture in 2026 looks very different from even a couple of years ago. Manufacturers now sell directly to self-paying patients at a fraction of the old list prices, pills have arrived as a cheaper option, and Medicare has started covering weight-loss GLP-1s through a temporary program. There are more ways to make this affordable than most people realize.

This guide walks through what you'll actually pay per month, where the prices come from, and how to plan for a full year. Prices change often, so we link each one to its source. Always check the manufacturer's page before you budget.

GLP-1 Cost in 2026: Self-Pay Prices by Medication

If you're paying without insurance, the biggest change is that both Novo Nordisk and Eli Lilly now sell directly to patients through their own pharmacy programs, NovoCare Pharmacy and LillyDirect. You still need a valid prescription, but you skip the insurance maze entirely.

Here's what the manufacturers list for self-pay patients as of September 2026. The yearly column simply multiplies the monthly price by 12, so you can see what staying on a given dose would cost over a year.

Sources: NovoCare Wegovy savings offer, NovoCare Ozempic offer, and Zepbound coverage and savings.

A few details matter here. New patients get a lower starting price for semaglutide. Novo Nordisk offers new self-pay patients Wegovy or Ozempic at $199 a month for the first two monthly fills of the 0.25 mg and 0.5 mg doses, through December 31, 2026. Compared with the regular $349 price, that saves $300 over those two months.

Zepbound's higher-dose price has a condition. Lilly's $449 price for 7.5 mg and above applies when you refill within 45 days of your previous delivery. Miss that window and Lilly says regular prices of $499 to $699 a month apply. If you're on a higher dose, setting a refill reminder is literally worth money.

Foundayo is the newest option. Lilly's Foundayo (orforglipron), a GLP-1 pill, was approved by the FDA on April 1, 2026. Lilly says self-pay pricing starts at $149 a month for the lowest dose (Lilly).

These are the manufacturers' prices. Pharmacies and telehealth services that bundle the medication with a consultation often charge more, so compare the total you'll pay, not just the drug price.

Cost Per Month: What Changes the Number

The table makes it look simple, but your actual monthly cost depends on a few things.

Your dose. Most GLP-1 treatment starts at a low dose and steps up over the first few months, under your prescriber's direction. For Zepbound and Wegovy pills, the price rises with the dose, so your first months often cost less than your later ones. Budget for the dose you're likely to end up on, not just the starting price.

Pill versus injection. The Wegovy pill's lower doses and Foundayo's starting dose are among the cheapest self-pay options available. Whether a pill is right for you is a conversation for your prescriber, since the pills and injections have different dosing rules and results.

Insurance, if you have it. With eligible commercial coverage, manufacturer savings cards can bring the cost down to as little as $25 a month for Wegovy, Zepbound, and Foundayo. That's $300 over a year. Savings caps and eligibility rules apply, and government insurance is generally excluded.

Everything around the medication. Provider visits, lab work, and telehealth subscription fees all add to the real monthly cost. We'll come back to these.

To put it in perspective, staying on regular-price Wegovy injections for a year costs $4,188 at $349 a month. Staying on higher-dose Zepbound at $449 a month, refilled on time, costs $5,388. Those are real numbers, and they're worth knowing before you start rather than a few months in.

Medicare: The New $50 GLP-1 Bridge

For years, Medicare Part D couldn't cover drugs used only for weight loss. That changed on July 1, 2026, when CMS launched the Medicare GLP-1 Bridge, a temporary demonstration running through December 31, 2027 (CMS).

Under the Bridge, eligible Part D enrollees pay a $50 copay per month for Foundayo, Wegovy (injection and tablets), or the Zepbound KwikPen when used to reduce excess body weight and maintain weight loss. That's $600 over a year.

There are conditions. Your provider needs to submit a prescription and a prior authorization request, and you need to meet one of CMS's criteria. These include a BMI of 35 or more, a BMI of 30 or more with heart failure, uncontrolled high blood pressure, or chronic kidney disease stage 3a or higher, or a BMI of 27 or more with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease. If you're on Medicare, ask your doctor whether you qualify.

Insurance: Still the Wild Card

Outside Medicare, insurance coverage for weight-loss GLP-1s remains inconsistent. Many plans cover these medications for type 2 diabetes but not for weight management, even when the active ingredient is the same.

If you have insurance, start by checking your plan's formulary, which is its list of covered medications. Look for Wegovy, Zepbound, and Foundayo specifically, and check whether prior authorization or step therapy is required. Step therapy means trying other options first before the plan will pay for the one your doctor prescribed.

If your claim is denied, don't assume that's the end. Your provider can file an appeal with documentation of medical necessity, such as your BMI, weight-related conditions like sleep apnea or high blood pressure, and what you've already tried. Formularies can also change each year during open enrollment, so it's worth rechecking your options every fall.

What About Compounded GLP-1s?

During the shortages of 2023 and 2024, compounded semaglutide and tirzepatide were widely available at lower prices. That window has largely closed. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, and the grace periods that let pharmacies keep making copies ended in 2025 (FDA).

Compounded GLP-1s are not FDA approved, and the FDA has warned about dosing errors with them, including patients who took several times their intended dose after confusing units and milligrams (FDA). With manufacturer self-pay prices now starting at $149 to $349 a month, the price gap that once made compounding appealing is much smaller than it was.

If you're currently on a compounded product, talk with your prescriber about switching. Doses don't always translate one-to-one between products, so don't make the switch on your own.

Online "Deals": Proceed With Caution

The internet is full of cheap GLP-1 offers, including vials labelled "for research use only" or "not for human consumption." The FDA has warned companies selling semaglutide, tirzepatide, retatrutide, and similar drugs this way (FDA).

Products from unregulated sources may have the wrong amount of active ingredient, contaminants, or none of the drug at all. The savings aren't worth the risk, especially now that legitimate self-pay prices have come down so much. If you're comparing options, our guide to how to reconstitute retatrutide explains why investigational drugs sold online aren't a shortcut.

Patient Assistance and Other Help

If you can't afford even the reduced prices, there are still places to look. Ask your prescriber or pharmacist whether a manufacturer assistance program applies to you, and check nonprofit organizations such as NeedyMeds and the Patient Advocate Foundation maintain databases of assistance programs.

Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) can generally be used for prescription medications, which gives you a tax advantage on what you pay out of pocket. Check your plan's rules for what qualifies.

Some people also use pharmacy payment plans or medical credit cards to spread out costs. If you go that route, read the interest terms carefully, since promotional rates often jump after a set period.

Budgeting for the Whole Year

When you plan for peptide therapy, think beyond the monthly medication price. Factor in provider visits and lab work, which most people need periodically, and any telehealth subscription fees. These can add several hundred dollars a year.

Also plan for price changes. Introductory offers end, programs change, and Novo Nordisk says it can modify or cancel its self-pay program at any time. The current $199 semaglutide intro offer, for example, runs through December 31, 2026. Build in a buffer so a price change doesn't force you to stop suddenly.

It's also worth thinking about the long term. Many people stay on these medications for a long time. Ask your prescriber what a realistic treatment length looks like for you, and budget for it honestly.

Track Your Costs and Your Results

Keeping a record of both what you spend and how you're doing makes every decision easier. It helps you judge whether a medication is worth the cost, and it's useful evidence if you ever need to appeal an insurance denial.

PeptideKit lets you log each dose, track side effects and progress over time, and set reminders so you never miss an injection. Pair that with a simple note of each refill date and price, and you'll always know when your next order is due, which matters when your price depends on refilling within a set window.

Frequently Asked Questions

How much does peptide therapy cost per month in 2026?

For FDA-approved GLP-1 medications bought directly from the manufacturer without insurance, listed self-pay prices currently run between $149 and $499 a month depending on the medication and dose, and more for Zepbound's higher doses if you miss the 45-day refill window. With eligible commercial insurance and a savings card, some people pay as little as $25 a month. Eligible Medicare patients pay $50 a month through the GLP-1 Bridge.

How much does a GLP-1 cost without insurance?

As of September 2026, Wegovy injections are $349 a month on NovoCare self-pay ($199 for the first two months for new patients), Ozempic is $349 to $499, Zepbound is $299 to $449 when refilled on time, and the Wegovy pill and Foundayo start at $149 for the lowest dose.

Does Medicare cover GLP-1s for weight loss in 2026?

Yes, temporarily. The Medicare GLP-1 Bridge runs July 1, 2026 through December 31, 2027 and covers Foundayo, Wegovy, and the Zepbound KwikPen for eligible Part D enrollees at $50 a month. You need prior authorization and must meet BMI and health criteria.

What is the cheapest GLP-1 medication?

Among manufacturer self-pay prices, the lowest listed prices are $149 a month for the starting dose of the Wegovy pill and of Foundayo. The cheapest option for you depends on your insurance, your dose, and what your prescriber recommends.

Is compounded semaglutide or tirzepatide still cheaper?

The FDA has ended the shortage-related flexibility that allowed widespread compounding, and compounded GLP-1s are not FDA approved. With manufacturer self-pay prices now much lower, the price gap is smaller than it used to be. Talk to your prescriber before switching products.

Why did my Zepbound price go up?

Lilly's $449 self-pay price for 7.5 mg and higher doses requires refilling within 45 days of your previous delivery. If you miss that window, Lilly says regular prices of $499 to $699 a month apply.

The Bottom Line

GLP-1 therapy is still a real expense, but in 2026 it's far more accessible than it was. Self-pay prices start at $149 a month, savings cards can bring insured costs down to $25, and Medicare now offers a $50 option for people who qualify.

Compare your options carefully, watch for introductory offers ending, refill on time when your price depends on it, and steer clear of unregulated online sellers. And keep a clear record of your doses, costs, and results with PeptideKit so you can judge whether the investment is working for you.

Always consult with qualified healthcare professionals before starting any peptide therapy protocol. This information is for educational purposes only and does not constitute medical advice.